Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00192803

Enrollment

Registered

2005-09-19

Start date

Unknown

Completion date

Unknown

Last updated

2006-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NIDDM

Keywords

niddm, ace2, NIDDM patients

Brief summary

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan. This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Interventions

DRUGcandesartan

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

ECT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Signed informed consent * Non-smokers * Type II DM diagnosed patients * Blood pressure \< 135/90 * Serum HbA1C \> 7% * Serum creatinine \< 1mg% * Urine microalbumin \< 300 mg/day * Body mass index (BMI) \< 35 kg/m2

Exclusion criteria

* Insulin-dependent diabetic patients * Patient with persistent microalbuminuria * Patient with history of severe hypertension * Congestive heart failure * Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications. * Patient with major hepatic disease

Design outcomes

Primary

Measure	Time frame
ACE and ACE2 activities in monocytes	—

Countries

Israel

Contacts

Primary ContactShlomo Keidar, MD

skeidar@rambam.health.gov.il97248542518

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026